

TEST SUMMARY

Cytokine Release Syndrome Panel

Diagnosing Cytokine Release Syndrome (CRS) immediately is vital as it can rapidly escalate into a life-threatening condition. CRS results from an excessive immune response, often triggered by immunotherapies like chimeric antigen receptor T cell therapy (CAR-T), bone marrow transplant or infections, leading to a massive release of pro-inflammatory cytokines. The degree of elevation of markers often correlates with the severity of the clinical syndrome. For example, large elevations in IL-6 supports the diagnosis of CRS.

Design note: panel content based on the 2024 recommendations from 25 physician key opinion leader (KOLs) from major academic medical centers from across the US (including: CHOP, UCSF (2), Stanford, Children's Alabama (2), Kaiser SF, Valley Children's, CHOC (3), Phoenix Children's, Cook Children's, UC Davis, Stanford Children's, University of Michigan Health, Johns Hopkins, Hershey MC, St. Jude, NIH, St. Louis Children's, Loma Linda Children's, UCSD, and UC Davis).

Please visit machaondiagnosics.com for more information.

References: 1. Fajgenbaum and June, 2020, New England Journal of Medicine. 2. Bakos et al 2023, Biomedicine and Pharmacotherapy. 3. Li et al 2021, Nature.

SPECIMEN REQUIREMENTS

Three aliquots, 1mL (EDTA Plasma)

STABILITY

Frozen

CPT CODE

83520x10

83529

86160

METHODOLOGY

Automated ELISA

TURNAROUND TIMES

Routine TAT: <5 days (M-F)

STAT TAT: <24 hours (M-F)

TARGET LIST

CXCL9	IL-18
CXCL10	IFN-gamma
IL-1 beta	sIL-2RA
IL-4	TNF-alpha
IL-6	Fas ligand
IL-10	sC5b-9

ABOUT US:

Machaon Diagnostics is a clinical reference laboratory, specializing in coagulation, platelets, complement, genetics and rare disease.



WHY CHOOSE US?

- ✓ Fast turnaround time
- ✓ Clinical consultation
- ✓ Critical Results called to physician